Skip to main content
. 2017 Jan-Feb;33(1):48–52. doi: 10.12669/pjms.331.12352

Table-II.

Rapid Virologic Response during the Treatment with Sofosbuvir (Zoval).

Response* n (%)
All patients during treatment
 Week 2 16/19 (84.2)
 Week 4 563/573 (98.2)
Cirrhotic patients (triple therapy) 19/23 (82.6)
Relapse patients to interferon 23/26 (88.4)
Non responder to interferon (triple therapy) 6/7 (85.7)
With or without interferon
 Double therapy 497 (86.7)
 Triple Therapy 76 (13.2)
*

An HCV RNA level of 25 IU per milliliter (lower limit of quantification).